8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 6, 2026·SEC
Material company update
Mar 23, 2026·SEC
Surrozen, Inc.(SRZN)Earnings, Financials & Key Ratios
SRZN•NASDAQ
$23.01
Price updated Jul 7, 2026
AboutSurrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.Show more
- Revenue$3M-67.4%
- EBITDA-$42M-72.4%
- Net Income-$242M-280.8%
- EPS (Diluted)-32.37-49.4%
- Gross Margin84.56%-15.4%
- EBITDA Margin-1195.14%-428.5%
- Operating Margin-1210.58%-405.1%
- Net Margin-6960.77%-1066.8%
SRZN Price & Volume
Surrozen, Inc. (SRZN) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Milestone Realization
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Exhaustion
Key Thesis Takeaways
- Surrozen operates as a high-risk, pre-revenue biotechnology firm whose valuation is entirely contingent upon the successful clinical progression of its bi-specific antibody platform.
- The company faces significant existential pressure as its R&D-heavy business model continues to erode shareholder equity, which has plummeted to a deficit of $278.1 million as of 2026Q1.
- Investors should remain cautious, as the firm's reliance on volatile, non-recurring milestone payments provides little visibility into long-term commercial sustainability.
Verdict Logic
the company's accumulated deficit of $654.8 million and the persistent disconnect between net income and cash burn indicate a high probability of future equity dilution for shareholders.
SRZN Growth Metrics
Surrozen, Inc. (SRZN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-34.72%
TTM-35.61%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-319.27%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-68.97%
Return on Capital
10 Years-63.67%
5 Years-62.07%
3 Years-68.58%
Last Year-64.78%
SRZN Recent Earnings
Surrozen, Inc. (SRZN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 1/12 qtrs (50%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$4.63-233.1%
$1.39
Rev
$5M+25.0%
$4M
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$7.59-438.3%
$1.41
Rev
$514,000-22.2%
$661,000
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$3.61-208.5%
$1.17
Rev
$983,000
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$1.14+7.3%
$1.23
Rev
$983,000
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $4.63vs $1.39-233.1% | $5Mvs $4M+25.0% |
| Q2 2026 | Mar 23, 2026 | $7.59vs $1.41-438.3% | $514,000vs $661,000-22.2% |
| Q4 2025 | Nov 7, 2025 | $3.61vs $1.17-208.5% | $983,000 |
| Q3 2025 | Aug 8, 2025 | $1.14vs $1.23+7.3% | $983,000 |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Surrozen, Inc. (SRZN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $23.01 | $172.06M | -0.71 | -67.37% | -6960.77% | — | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $9.68 | $506.78M | -2.14 | -92.84% | -260.92% | -49.88% | — |
Compare SRZN vs Peers
Surrozen, Inc. (SRZN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SRZN SEC Filings & Documents
Surrozen, Inc. (SRZN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SRZN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SRZN Frequently Asked Questions
Surrozen, Inc. (SRZN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Surrozen, Inc.'s revenue?
Surrozen, Inc. (SRZN) reported $7.5M in revenue for fiscal year 2025.
How fast is Surrozen, Inc. growing?
Surrozen, Inc. (SRZN) saw revenue decline by 67.4% over the past year.
Is SRZN profitable?
Surrozen, Inc. (SRZN) reported a net loss of $342.6M for fiscal year 2025.
Dividend & Returns
What is Surrozen, Inc.'s free cash flow?
Surrozen, Inc. (SRZN) had negative free cash flow of $33.7M in fiscal year 2025, likely due to heavy capital investments.